Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$4.41
0.102.32%
At close: -
$4.50
0.092.04%
After Hours: 7:45 PM EDT
Comments
Loading...
iBio Analyst Ratings and Price Targets | NASDAQ:IBIO | Benzinga
iBio Inc has a consensus price target of $3.69 based on the ratings of 5 analysts. The high is $6 issued by LUCID CAPITAL MARKETS on December 17, 2024. The low is $0.17 issued by Cantor Fitzgerald on October 7, 2022. The 3 most-recent analyst ratings were released by LUCID CAPITAL MARKETS, Brookline Capital, and Chardan Capital on December 17, 2024, July 22, 2024, and June 3, 2024, respectively. With an average price target of $4.87 between LUCID CAPITAL MARKETS, Brookline Capital, and Chardan Capital, there's an implied 8.15% upside for iBio Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
LUCID CAPITAL MARKETS
Brookline Capital
Chardan Capital
Cantor Fitzgerald
1calculated from analyst ratings
Analyst Ratings for iBio
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 12/17/2024 | Buy Now | 33.33% | LUCID CAPITAL MARKETS | Dev Prasad 43% | → $6 | Initiates | → Buy | Get Alert |
| 07/22/2024 | Buy Now | -20% | Brookline Capital | Kemp Dolliver32% | → $3.6 | Initiates | → Buy | Get Alert |
| 06/03/2024 | Buy Now | 11.11% | Chardan Capital | Keay Nakae58% | $5 → $5 | Maintains | Buy | Get Alert |
| 05/28/2024 | Buy Now | 11.11% | Chardan Capital | Keay Nakae58% | → $5 | Initiates | → Buy | Get Alert |
| 02/16/2023 | Buy Now | — | JMP Securities | Roy Buchanan36% | — | Downgrade | Market Outperform → Market Perform | Get Alert |
| 10/07/2022 | Buy Now | -96.22% | Cantor Fitzgerald | Kristen Kluska71% | $1250 → $85 | Downgrade | Overweight → Neutral | Get Alert |
FAQ
What is the target price for iBio (IBIO) stock?
The latest price target for iBio (NASDAQ:IBIO) was reported by LUCID CAPITAL MARKETS on December 17, 2024. The analyst firm set a price target for $6.00 expecting IBIO to rise to within 12 months (a possible 33.33% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for iBio (IBIO)?
The latest analyst rating for iBio (NASDAQ:IBIO) was provided by LUCID CAPITAL MARKETS, and iBio initiated their buy rating.
When was the last upgrade for iBio (IBIO)?
There is no last upgrade for iBio
When was the last downgrade for iBio (IBIO)?
The last downgrade for iBio Inc happened on February 16, 2023 when JMP Securities changed their price target from N/A to N/A for iBio Inc.
When is the next analyst rating going to be posted or updated for iBio (IBIO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of iBio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for iBio was filed on December 17, 2024 so you should expect the next rating to be made available sometime around December 17, 2025.
Is the Analyst Rating iBio (IBIO) correct?
While ratings are subjective and will change, the latest iBio (IBIO) rating was a initiated with a price target of $0.00 to $6.00. The current price iBio (IBIO) is trading at is $4.50, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.